Physician profile
Gary E Eggleston
NPI 1487629515
$405.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.22 · 2020: $11.97 · 2021: $60.63 · 2022: $50.36 · 2023: $143 · 2024: $52.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181 · Education: $14.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.01 |
| Education | $14.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $113.84 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.66 | 2019-2022 | |
| Pfizer INC. | $31.42 | 2019-2022 | |
| Boston Scientific Corporation | $30.33 | 2023 | Watchman Access System |
| Glaxosmithkline, LLC. | $29.80 | 2023-2024 | Bexsero |
| Advanced Oxygen Therapy INC. | $18.61 | 2023 | Topical Oxygen Chamber For Extremities |
| Amgen INC. | $18.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.54 | 2019 | |
| Lilly USA, LLC | $17.39 | 2021 | |
| Dexcom, INC. | $16.93 | 2022 | |
| Abbvie INC. | $15.18 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $14.85 | 2021 | |
| Opko Pharmaceuticals, LLC | $14.27 | 2023 | Rayaldee |
| Merck Sharp & Dohme LLC | $12.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Eggleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.